RecruitingUpper Urinary Tract Urothelial CarcinomaUrothelial Carcinoma

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

14 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal solution), instilled in the upper urinary tract (UUT) of patients with low-grade upper tract urothelial cancer (LG-UTUC).

Sponsor: UroGen Pharma Ltd.

You may qualify if…

✓ 1. Provide written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and protocol.
✓ 2. Naive or recurrent patients with LG, non-invasive UTUC in the pyelocalyceal system, with the following disease characteristics:
✓ 1. At least 1 measurable papillary LG tumor, evaluated visually, ≤ 15 mm. The largest lesion should not exceed 15 mm. Debulking to ≤ 15 mm is permitted.
✓ 2. Biopsy taken from at least 1 tumor located above the ureteropelvic junction revealing LG urothelial carcinoma (UC). Patients who have been biopsied within 8 weeks before Screening for this study and shown to have LG UC may have these historical biopsies used for enrollment into the study and do not require repeat biopsy during Screening.
✓ 3. Patient should have at least 1 remaining papillary LG tumor evaluated visually with a diameter of at least 5 mm post-biopsy.
✓ 4. Wash urine cytology sampled from the pyelocalyceal system documenting the absence of high-grade (HG) UC, diagnosed not more than 8 weeks before Screening.
✓ 5. Patients with bilateral LG-UTUC may be enrolled if at least 1 side meets the inclusion criteria for the study and if the other kidney does not require further treatments. (The disease in the other kidney must be completely ablated before receiving treatment in the study.) Note: If both upper tracts meet inclusion criteria, the treating urologist in consultation with the sponsor's medical monitor can decide which side to treat in the study. The pyelocalyceal system not under study must be free of cancer before the first instillation on the side to be treated in the study.
✓ 3. Patients with Eastern Cooperative Oncology Group (ECOG) performance status \< 3 (with Karnofsky \> 40).

You may not qualify if…

✕ 1. UC specific exclusions:
✕ 1. Patient received Bacillus Calmette-Guérin (BCG) treatment for UC during the 6 months before enrollment.
✕ 2. The patient has untreated concurrent UC in locations other than the target area (unless treated and resolved during Screening); ie, ureteral and lower urinary tract tumors must be completely ablated before entry.
✕ 3. Patient has a history of carcinoma in situ (CIS) in the urinary tract.
✕ 4. Patient has a history of invasive UC in the past 5 years.
✕ 5. Patient has a history of HG papillary UC in the urinary tract in the past 2 years.
✕ 2. Patient is actively being treated or intends to be treated with systemic chemotherapy during the duration of the study.
✕ 3. Any other malignancy diagnosed within 2 years before enrollment with the exception of: